ArticleAmerican journal of respiratory and critical care medicine2022
CYFRA 21-1 Predicts Progression in Idiopathic Pulmonary Fibrosis: A Prospective Longitudinal Analysis of the PROFILE Cohort.
Open access · greenAbstract read
In one paragraph
Article in American journal of respiratory and critical care medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 45 citations in OpenAlex.
- Trial
- Association of CYFRA 21-1 with quantitative CT-defined fibrotic progression in idiopathic pulmonary fibrosis.BMC pulmonary medicine · 2026Article
- A Nomogram Model for Early Mortality Risk Stratification in Elderly Patients with Idiopathic Pulmonary Fibrosis: An Integrative Analysis of Serum Biomarkers and Pulmonary Function Parameters.Journal of clinical medicine · 2026Article
- Regulation of Keratin Chemical Modifications: Potential Molecular Mechanisms in Proliferative Diseases.International journal of molecular sciences · 2026Review
- Lung ultrasound plus transthoracic echocardiography for severity stratification in pulmonary fibrosis: a cross-sectional diagnostic study.BMC pulmonary medicine · 2026Article
- Reprogrammed Fibrotic Niche Fuels Lung Cancer Initiation and Reciprocal Remodeling.International journal of biological sciences · 2026Review
- Gradient elevation of serum CYFRA21-1 and its synergy with KL-6 for risk stratification in rheumatoid arthritis-associated interstitial lung disease.Frontiers in medicine · 2026Article
- Distinct phenotypic clusters associated with progressive pulmonary fibrosis in anti-synthetase syndrome-associated interstitial lung disease.Frontiers in immunology · 2026Article
- Retrospective analysis of the clinical features and prognosis of idiopathic pulmonary fibrosis combined with lung cancer.BMC cancer · 2025Article
- Serum CYFRA21-1 as a novel biomarker for predicting progressive pulmonary fibrosis in non-IPF interstitial lung disease, a cohort study.BMC pulmonary medicine · 2025Article
- A serum biomarker-based index for predicting progressive pulmonary fibrosis in patients with anti-synthetase syndrome: the LOCCM index.Respiratory research · 2025Article
- Proteomic Biomarkers of Survival in Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease.American journal of respiratory and critical care medicine · 2025Article
- Blurred Boundaries: Rethinking Disease Classifications in Interstitial Lung Disease Using Molecular Signals.American journal of respiratory and critical care medicine · 2025Article
- Circulating prostasin is an independent marker of mortality risk in patients with idiopathic pulmonary fibrosis.ERJ open research · 2025Article
- A deeper evaluation of cytokeratin fragment 21-1 as a lung cancer tumor marker and comparison of different assays.Biosensors & bioelectronics: X · 2025Article
- Clinical analysis of patients with idiopathic pulmonary fibrosis concurrent with surgery resectable lung cancer: a retrospective cohort study from perspective of ILD physicians.BMC pulmonary medicine · 2025Article
- Serum biomarker changes in pulmonary fibrosis with lung cancer and their correlation with patient survival prognosis.American journal of cancer research · 2025Article
- Clinical significance of cytokeratin 19 fragment in COVID-19 patients: a retrospective study.Frontiers in public health · 2025Article
- A narrative review on lung injury: mechanisms, biomarkers, and monitoring.Critical care (London, England) · 2024Review
- Reply to FujimotoAmerican journal of respiratory and critical care medicine · 2024Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
16 authors at 6 institutions in 3 countries.
Philip L MolyneauxNational Heart and Lung Institute, Imperial College London, London, United Kingdom.
William A FahyDiscovery Medicine, GlaxoSmithKline, Stevenage, United Kingdom.
Adam J ByrneNational Heart and Lung Institute, Imperial College London, London, United Kingdom.
Rebecca BraybrookeDivision of Respiratory Medicine, University of Nottingham, Nottingham, United Kingdom.
Peter SaundersNational Heart and Lung Institute, Imperial College London, London, United Kingdom.
Richard ToshnerNational Heart and Lung Institute, Imperial College London, London, United Kingdom.
Gesa AlbersNational Heart and Lung Institute, Imperial College London, London, United Kingdom.
Felix ChuaNational Heart and Lung Institute, Imperial College London, London, United Kingdom.
Elisabetta A RenzoniNational Heart and Lung Institute, Imperial College London, London, United Kingdom.
Athol U WellsNational Heart and Lung Institute, Imperial College London, London, United Kingdom.
Yakshitha KarkeraBiostatistics, GlaxoSmithKline R&D, Bangalore, India; and.
Eunice OballaDiscovery Medicine, GlaxoSmithKline, Stevenage, United Kingdom.
Gauri SainiDivision of Respiratory Medicine, University of Nottingham, Nottingham, United Kingdom.ORCID 0000-0002-7786-737X
Andrew G NicholsonNational Heart and Lung Institute, Imperial College London, London, United Kingdom.
R Gisli JenkinsNational Heart and Lung Institute, Imperial College London, London, United Kingdom.
Toby M MaherNational Heart and Lung Institute, Imperial College London, London, United Kingdom.ORCID 0000-0001-7192-9149
Guy's and St Thomas' NHS Foundation Trust · GBImperial College London · GBGlaxoSmithKline (United Kingdom) · GBUniversity of Nottingham · GBGlaxoSmithKline (India) · INUniversity of Southern California · US
Funding
Department of Health CS-2013-13-017HSRD VA CDA 13-017Medical Research Council G0901226
Abstract
PubMed holds no abstract for this paper.
Indexed as
Idiopathic Pulmonary FibrosisAntigens, NeoplasmBiomarkersDisease ProgressionHumansKeratin-19Prospective Studiesantigen CYFRA21.1Antigens, NeoplasmBiomarkersKeratin-19biomarkersclinical trialsepitheliuminterstitial lung disease
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.